Profitelligence Profitelligence · Filing Ledger Open A research →

Form 8-K · Current Report · Filed 2026-05-27

Agilent Technologies Reports Strong Q2 2026 Financial Results and Appoints New Chief Accounting Officer

Agilent Technologies, Inc. reported strong second-quarter fiscal year 2026 financial results, with revenue of $1.83 billion, representing a 10.0% reported growth and 6.3% core growth compared to the second quarter of 2025. The company's GAAP operating margin was 21.7%, while the non-GAAP operating margin expanded by 130 basis points year-over-year to 26.4%. GAAP net income was $339 million, or $1.20 per share, and non-GAAP net income was $423 million, or $1.49 per share. Agilent also raised its fiscal year 2026 revenue guidance to a range of $7.39 billion to $7.49 billion, with non-GAAP EPS guidance now expected in the range of $6.00 to $6.10. Additionally, the company appointed Tim Downs as the new Vice President, Chief Accounting Officer, effective as of the first business day following the filing of the quarterly report on Form 10-Q for the quarter ended April 30, 2026.

Filer
Agilent Technologies Inc. A · NYSE
Filed
Accession
0001090872-26-000052
CIK
0001090872
Signal
High impactHealthcare

Items reported

Item events

Reported Item

Earnings Beat General Statement New CEO Appointed

Market reaction

Close before filing

$115.08

Next session

+17.6%

Since filing

+20.2%

Latest close

$138.37

What happened, not what will happen — closing prices around the filing date.

Precedent

Previous filings from A reporting the same item, with the next session's move:

Insider tape

Within 45 days of this filing, A insiders reported 5 Form 4 transactions — net selling of $321K.

Full A insider history →

About Agilent Technologies Inc.

Agilent Technologies Inc. is a global leader in the development and provision of life sciences, diagnostics, and applied chemical markets. Primarily focused on delivering superior analytical instruments, software, services, consumables, and reagents, the company plays a critical role in supporting the research needs of pharmaceutical, biotechnology, and government laboratories. Agilent's robust portfolio includes innovative solutions for genomics, proteomics, and metabolomics, aiding in critical areas such as disease research, food safety, and environmental analysis. Established in 1999 as a spin-off from Hewlett-Packard, the company leverages its heritage of technological innovation to enhance analytical capabilities for its clients. Agilent's significant contributions to health and safety applications underscore its importance in advancing scientific understanding and supporting public health initiatives worldwide.

Exchange NYSE Industry Diagnostics & Research Company website ↗

Never miss another A filing

Profitelligence watches EDGAR around the clock and alerts you within seconds.

Set up free alerts